Back to Agendas
Session 1B: Non Clinical Track: siRNA Conjugates
Session Chair(s)
Michael Placke, PhD
Senior Vice President, Drug Safety and Metabolism
Alnylam Pharmaceuticals, United States
Barbara Wilcox, PhD
Pharmacologist, OMPT, ODEI, DNP, OND, CDER
FDA, United States
The focus of this session is primarily GalNac siRNA conjugates and associated PK/PD issues to include plasma, liver, and tissue distribution, metabolites, and persistence. The nonclinical toxicology for seven different GalNac siRNA conjugates will be presented as well as data for an antisense conjugate.
Speaker(s)
Drug Metabolism and Pharmacokinetic (DMPK) Properties of siRNA-GalNAc Conjugates
Anshul Gupta, DVM, MS
Alnylam Pharmaceuticals, United States
Lead Scientist, Drug Safety & Metabolism
Toxicity, Pathology and Safety Profiles of siRNA GalNAc Conjugates
Natalie Keirstead, DVM, PhD
Alnylam Pharmaceuticals, United States
Director of Pathology, Drug Safety & Metabolism
Targeted Delivery of 2'-MOE ASO to Hepatocytes Using GalNAc Conjugates: Impact on Potency, Therapeutic Index, and Pharmacokinetics
Scott Henry, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Nonclinical Development
Locked Nucleic Acid: Enabling RNA Therapeutics
Mads Aaboe Jensen, PhD, MSc
Roche Innovation Center Copenhagen A/S, Denmark
Principal Scientist
Have an account?